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nalysis in Nonhypercholesterolemic
atients With Coronary Artery Disease
eisuke Watanabe, MD,* Seigo Sugiyama, MD, PHD,* Kiyotaka Kugiyama, MD, PHD,‡
samu Honda, MD,* Hironobu Fukushima, MD,* Hidenobu Koga, MD,* Yoko Horibata, MD,*
oshinori Hirai, MD, PHD,† Tomohiro Sakamoto, MD, PHD,* Michihiro Yoshimura, MD, PHD,*
asuyuki Yamashita, MD, PHD,† Hisao Ogawa, MD, PHD*
umamoto and Yamanashi, Japan
OBJECTIVES This study examined whether intensive cholesterol-lowering therapy with statins in nonhy-
percholesterolemic patients is effective in improving echolucency of vulnerable plaques
assessed by ultrasound with integrated backscatter (IBS) analysis.
BACKGROUND Atherosclerotic plaque stabilization is a promising clinical strategy to prevent cardiovascular
events in patients with coronary artery disease (CAD). There is a correlation between
coronary and carotid plaque instability, and echolucent plaques are recognized as vulnerable
plaques.
METHODS Consecutive nonhypercholesterolemic patients with CAD were randomly assigned Adult
Treatment Panel-III diet therapy (diet group; n  30) or pravastatin (statin group; n  30).
Echolucent carotid plaques were monitored by measuring intima-media thickness (IMT) and
echogenicity by IBS for six months.
RESULTS Total cholesterol, low-density lipoprotein cholesterol (LDL-C), and high-sensitivity
C-reactive protein were significantly decreased in the statin group (from 197  15 mg/dl to
170 18 mg/dl [p 0.001]; from 131 14 mg/dl to 99 14 mg/dl [p 0.001]; and from
0.11 [0.04 to 0.22] mg/dl to 0.06 [0.04 to 0.11] mg/dl [p 0.05]; respectively), whereas only
total cholesterol was moderately reduced (from 193  24 mg/dl to 185  22 mg/dl [p 
0.05]) and LDL-C and triglycerides insignificantly reduced in the diet group. Significant
increases of echogenicity of carotid plaques were noted in the statin group but not in the diet
group (from 18.5  4.1 dB to 15.9  3.7 dB [p  0.001] and from 18.2  4.0 dB to
18.9 3.5 dB [p 0.13]; respectively) without significant regression of plaque-IMT values
in both groups.
CONCLUSIONS Statin therapy is rapidly effective in increasing echogenicity of vulnerable plaques without
regression of plaque size in nonhypercholesterolemic patients with CAD. Quantitative
assessment of carotid plaque quality by ultrasound with IBS is clinically useful for monitoring
atherosclerotic lesions by evaluating vulnerability of atheroma. (J Am Coll Cardiol 2005;46:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.04.0702022–30) © 2005 by the American College of Cardiology Foundation
l
a
t
i
c
a
c
t
c
p
v
l
f
e
neveral large clinical trials have demonstrated that lipid-
owering therapy with statins reduces cardiovascular events
1–3). Stabilization rather than regression of vulnerable
theroma is considered the major contributor to this bene-
cial effect (4). Recent detailed animal studies support the
laque stabilization hypothesis (5); however, clinical evi-
ence of plaque stabilization is uncertain and there are no
ractical indexes to assess the effectiveness of plaque stabi-
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oundation; Japan Heart Foundation; and the Suzuken Memorial Foundation.m
Manuscript received November 3, 2004; revised manuscript received April 13,
005, accepted April 19, 2005.ization therapy. Hence it is difficult for physicians to verify
chievement of plaque stabilization and to be able to assess
he efficacy of the treatment given their patients. Some hope
n this area derives from recent technologic advances that
an assist in the evaluation of atherosclerotic plaque vulner-
bility, such as plaque temperature (6), intravascular angios-
opy (7), intravascular ultrasound (8), and optical-coherence
omography (9), but these methods are generally compli-
ated, invasive, expensive, and hardly repeatable. Because
laque stabilization is a promising clinical strategy to pre-
ent cardiovascular complications in patients with estab-
ished coronary artery disease (CAD) (4), practical and
easible examinations to identify vulnerable plaques and to
valuate the effects of treatment on plaque stabilization are
eeded.
Carotid artery ultrasound is an established, validated
ethod for visualizing and quantifying atherosclerotic le-
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December 6, 2005:2022–30 Ultrasound Evaluation of Plaque Stabilizationions using a noninvasive and repeatable procedure (10,11)
hat has proved a strong indicator of CAD (12,13). In
ddition, it has been reported that there is a significant
orrelation between coronary and carotid artery plaque
nstability (14,15). Recently, plaque echogenicity assessed
y ultrasound with integrated backscatter (IBS) analysis has
een shown to predict lipid content of plaques, and echolu-
ent atherosclerotic plaques with low IBS values have been
ecognized as lipid-rich vulnerable lesions (16–19). Fur-
hermore, echolucent atheroma has been shown to contain
bundant macrophages (18,19), which play a central role in
laque destabilization. We have recently demonstrated that
etecting echolucent carotid plaques by ultrasound with IBS
an predict coronary events in patients with stable CAD
14). Therefore quantitative assessment of carotid plaque
chogenicity with IBS may be a useful clinical surrogate
arker for evaluating plaque vulnerability. In the present
tudy, we identified and monitored vulnerable carotid
laques by quantitative ultrasound analysis with IBS in
onhypercholesterolemic patients with CAD so as to eval-
ate the usefulness of this strategy in assessing treatment
imed at plaque stabilization.
ETHODS
atients. This research was designed as an open-label
rospective randomized study. Eligible for entry into this
tudy were nonhypercholesterolemic patients (total choles-
erol 220 mg/dl) who underwent elective and diagnostic
oronary angiography at Kumamoto University Hospital
etween 2001 and 2003 because of an abnormality in the
lectrocardiogram or angina-like chest symptoms on effort.
ll patients underwent carotid ultrasound examination to
etermine the presence of echolucent carotid plaques. Sixty
onhypercholesterolemic patients with CAD who had
cholucent carotid plaques were enrolled. All patients had
ngiographic documentation of organic stenosis (50%) in
1 major coronary artery (single-vessel disease, n  24;
wo-vessel disease, n  21; three-vessel disease, n  15).
atients were randomly divided into two treatment groups:
iet group (n  30) and statin group (n  30). Diet group
atients received dietary counseling and adopted the Adult
reatment Panel-III lipid-lowering diet. Statin group pa-
ients initially received pravastatin 10 mg/day, which was
Abbreviations and Acronyms
cIBS  calibrated integrated backscatter
CAD  coronary artery disease
HDL-C  high-density lipoprotein cholesterol
hsCRP  high-sensitivity C-reactive protein
IBS  integrated backscatter
IMT  intima-media thickness
LDL-C  low-density lipoprotein cholesterol
TC  total cholesterol
TG  triglyceridesncreased to a final dose of 20 mg/day as required to achieve (arget low-density lipoprotein cholesterol (LDL-C) levels of
100 mg/dl. Excluded were patients with severe valvular
isease, trauma within the prior month, severe cardiomy-
pathy, malignant tumor, infectious disease, chronic inflam-
atory disease, end-stage renal failure, autoimmune disease,
r acute coronary syndrome. Informed consent was obtained
rom all patients. The study protocol was constructed in
000 and approved by the ethics committee at Kumamoto
niversity Hospital.
ltrasound evaluation. Using an 11.0-MHz linear array
ransducer (SONOS-5500, Philips, Andover, Massachu-
etts), carotid ultrasound examination was performed at
aseline and follow-up. A single well-trained operator
erformed all carotid scans without having any information
n the clinical characteristics of the patients. Each common,
nternal, and external carotid artery was carefully imaged in
he anterior oblique, lateral, and posterior oblique planes to
dentify atherosclerotic lesions. On a longitudinal image of
ach carotid artery, intima-media thickness (IMT) was
efined as the distance from the leading edge of the
umen-intima interface to that of the media-adventitia
nterface. Atherosclerotic plaques were defined as lesions
ith focal IMT1.1 mm with localized protrusion of vessel
all into the lumen (14,20). Maximum IMT of plaques
plaque-IMTmax) was defined as the greatest axial thickness
n the carotid arteries (Fig. 1).
easurement of IBS. Integrated backscatter values of all
arotid atherosclerotic plaques were measured as described
reviously (14,16,18). For each plaque, conventional high-
esolution B-mode images were obtained. Atherosclerotic
laques on the acoustic density mode were analyzed using
he manual outlined definition of region of interest (ROI),
s shown in Figure 1. Instrument imaging adjustments such
s transmit power, focus, time-gain compensation, and gain
etting including the depth gain compensation curve were
ll set at fixed values, with the system control remaining
nchanged for the measurement of all plaques during
ollow-up. The averaged power of the IBS signal within the
OI was measured and displayed in decibels (dB). The
dventitia was adopted as the reference object in line with
revious studies (16–18,21,22). Relative IBS value of the
therosclerotic plaque was expressed as the difference be-
ween the IBS value of the plaque and that of the adventitia
i.e., calibrated IBS value [cIBS]  [intima-media IBS
alue]  [adventitia IBS value]). Based on several previous
eports of carotid echogenicity assessment with cIBS, we
rbitrarily defined carotid plaques with cIBS values –14.5
B as “echolucent plaques” (14,16,18). In this study, in-
raobserver variability for repeated measurements was 0.5 
.4 dB. No patient was found to have calcification severe
nough to prevent measurement of IBS.
agnetic resonance imaging evaluation of echolucent
arotid plaques. Recently, it was proposed that magnetic
esonance imaging (MRI) could evaluate carotid plaque
omponent noninvasively (23). Echolucent carotid plaques
plaque-IMTmax 4.0 mm) were imaged with a 1.5-T MR
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Ultrasound Evaluation of Plaque Stabilization December 6, 2005:2022–30canner (Magnetom Vision; Siemens, Erlangen, Germany)
nd phase-array surface coils. Fast spin-echo–based T1-
eighted (T1W), proton density-weighted (PDW), and
2-weighted (T2W) images as well as time-of-flight
TOF) images of the echolucent plaques were obtained by
tandardized protocol. The scan was centered on the tar-
eted carotid plaques with echolucent appearance, and the
verage scan time was 40 min. Carotid plaque component
as assessed using previously established criteria (23).
ollow-up. Before and after treatment, the same operator,
ho was blinded to patient treatment and assignment,
erformed all carotid ultrasound examinations (measure-
ent of plaque-IMTmax and cIBS). All ultrasound data at
aseline and follow-up were recorded on S-VHS videotapes
nd digital magneto-optical drives. The best projection of
igure 1. Representative ultrasound images of atherosclerotic carotid plaqu
hown by arrowheads. Plaque-IMTmax was measured in this mode as show
f interest (ROI) in the plaque (intima-media complex), and the blue dott
ode. Values of cIBS and plaque-IMTmax of this plaque are 19.6 dB a
ackscatter; ICA  internal carotid artery; IMT  intima-media thickne
Table 1. Baseline Clinical Characteristics of Pa
Pravastat
(n  30
Age (yrs) 69.9  8.8
Gender (male/female) 21/9
Smoking 11 (37%)
Hypertension 18 (60%)
Diabetes mellitus 8 (27%)
BMI (kg/m2) 23.6 (21.8–2
TC (mg/dl) 197  15
HDL-C (mg/dl) 49  13
LDL-C (mg/dl) 131  14
TG (mg/dl) 127 (96–150
hsCRP (mg/dl) 0.11 (0.04–0
IMTmax (mm) 2.19 (1.86–2
cIBS (dB) 18.5  4.1
Medication
Beta-blocker 8 (27%)
Calcium antagonist 26 (87%)
ACE inhibitor or ARB 16 (53%)
Nitrate 9 (30%)
Aspirin 29 (97%)
Diuretics 2 (7%)
ACE  angiotensin-converting enzyme inhibitor; ARB  a
calibrated integrated backscatter; HDL-C  high-density lipoprote
IMT  intima-media thickness; LDL-C  low-density lipoprotehe ultrasound probe was noted, and the distance from the
ifurcation of the common carotid artery to the target
laques was measured so as to record plaque loci. Further-
ore, where arterial calcification was evident this also was
sed as a landmark to identify the target plaque at follow-up.
eripheral blood samples were collected in the early morn-
ng before breakfast at the beginning of the study and
ollow-up period. Serum lipid parameters and high-sensitivity
-reactive protein (hsCRP) were measured in the hospital
aboratory. During the follow-up period, all patients received
he standardized medical therapy outlined in Table 1.
tatistical analysis. Results are expressed as mean  SD.
riglycerides, hsCRP, body mass index (BMI), and plaque-
MTmax are expressed as median and interquartile range.
requencies of gender, smoking, hypertension, and diabetes
th ultrasound analysis. (A) Regular B-mode image of carotid atheroma as
an arrow. (B) IBS-mode image. The red dotted line indicates the region
e indicates the ROI in the adventitia using the manual outline definition
.44 mm, respectively. CCA  common carotid artery; IBS  integrated
s
Diet
(n  30) p Value
69.1  9.6 0.74
21/9 —
12 (40%) 0.79
21 (70%) 0.42
6 (20%) 0.54
23.2 (22.0–24.8) 0.80
193  24 0.37
50  12 0.81
126  22 0.26
118 (92–144) 0.61
0.14 (0.05–0.28) 0.41
2.07 (1.68–2.42) 0.18
18.2  4.0 0.78
9 (30%) 0.77
27 (90%) 0.69
17 (57%) 0.79
13 (43%) 0.28
29 (97%) —
3 (10%) 0.64
nsin II receptor blocker; BMI  body mass index; cIBS es wi
n by
ed lin
nd 2tient
in
)
5.0)
)
.22)
.57)
ngiote
in cholesterol; hsCRP  high-sensitivity C-reactive protein;
in cholesterol; TC  total cholesterol; TG  triglycerides.
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December 6, 2005:2022–30 Ultrasound Evaluation of Plaque Stabilizationellitus were compared between the two groups using
hi-square analysis. Comparisons between the two treat-
ent groups were performed by unpaired t test (normally
istributed variables: age, total cholesterol [TC], LDL-C,
igh-density lipoprotein cholesterol [HDL-C], and cIBS)
nd nonparametric Mann-Whitney U test (triglycerides
TG], hsCRP, BMI, and plaque-IMTmax). Comparisons in
ach group from baseline to follow-up were assessed by
aired Student t test (changes in TC, LDL-C, HDL-C,
nd cIBS) and Wilcoxon signed rank test (changes in TG,
sCRP, and plaque-IMTmax). Associations between
hanges of continuous serum parameters (TC, LDL-C,
DL-C, TG, and hsCRP) and cIBS values were examined
y calculating Pearson correlation coefficients and linear
egression analysis. Multiple regression analysis was then
erformed with change of cIBS as the dependent variable
nd significant serum parameters as independent variables.
nivariate logistic regression analysis with covariates listed
n Table 1 was performed to determine effective factors for
mproving carotid echolucency. Statistical significance was
efined as p  0.05. All analyses were carried out by
tatView-5.0 software (Tokyo, Japan).
ESULTS
aseline clinical characteristics. Baseline clinical charac-
eristics of the patients are shown in Table 1. All 60 patients
ompleted the protocol. Medications were well tolerated
uring the follow-up period. Patients were followed for a
eriod of 6.2 0.8 months (statin group, 6.2 1.0 months;
iet group, 6.1  0.6 months; p  0.63) after starting
reatment. The final dose of pravastatin was 10 mg/day in
6 patients and 20 mg/day in 4 patients. There was no
ignificant difference in all baseline demographic parameters
etween the two groups (Table 1).
hange in lipoprotein and hsCRP levels. Table 2 shows
hanges of lipoprotein and hsCRP levels in the two study
roups. In the statin group, TC, LDL-C, and hsCRP levels
ignificantly decreased and HDL-C significantly increased
rom baseline to end of follow-up. In the diet group, only
C levels were moderately reduced (p  0.05). At the end
f follow-up, TC, LDL-C, and hsCRP levels were signif-
cantly lower in the statin group than in the diet group.
able 2. Follow-Up Data of Patients on Pravastatin Therapy and
Parameter
Pravastatin
Baseline F
C (mg/dl) 197  15 1
DL-C (mg/dl) 131  14
DL-C (mg/dl) 49  13
G (mg/dl) 127 (96–150) 120
sCRP (mg/dl) 0.11 (0.04–0.22) 0.06
laque-IMTmax (mm) 2.19 (1.86–2.57) 2.27
IBS (dB) 18.5  4.1 15p  0.01 vs. baseline; †p  0.05 vs. baseline; ‡p  0.01 at follow-up; §p  0.05 at follo
Abbreviations as in Table 1.ietary lipid-lowering therapy was significantly effective in
educing TC (from 193  24 mg/dl to 185  22 mg/dl;
 0.05); however, statin therapy produced more intensive
ipid-lowering effects than diet therapy (TC reduction 28
16 mg/dl and 8  16 mg/dl, respectively; p  0.001;
DL reduction: 33  13 mg/dl and 5  17 mg/dl,
espectively; p  0.001) (Fig. 2).
arotid plaque evaluation. Figure 3 shows representative
mages of the echolucent carotid plaque examined by both
igh-resolution ultrasound (Figs. 3A to 3C) and multispec-
ral MRI (Figs. 3D to 3G). The echolucent carotid plaques
ppeared hyperintense to isointense on T1W images, hy-
ointense on T2W images, isointense to hypointense on
DW images, and isointense on TOF images, indicating
hat echolucent plaque exhibits a lipid-rich vulnerable con-
ition by MRI criteria (23).
At baseline and follow-up, cIBS and plaque-IMTmax
alues were obtained in all patients (Tables 1 and 2).
epresentative IBS images of targeted carotid plaque at
aseline and follow-up are shown in Figure 4. At baseline,
IBS and plaque-IMTmax values were not significantly
ifferent between the two groups. At follow-up, echogenic-
ty assessed by cIBS values was significantly higher in the
tatin group than in the diet group (p  0.01). Significant
ncreases of echogenicity of the carotid plaques were ob-
erved in the statin group but not in the diet group (from
18.5  4.1 dB to 15.9  3.7 dB [p  0.001] and from
18.2  4.0 dB to 18.9  3.5 dB [p  0.13]; respec-
ively) (Fig. 5A). The increase of cIBS values was signifi-
antly greater in the statin group than in the diet group (2.7
2.3 dB vs. 0.7  2.3 dB; p  0.001) (Fig. 5B). A
ignificant increase of cIBS values by pravastatin was also
bserved in CAD patients with “normal” cholesterol levels
TC 200 mg/dl; n  42) [cIBS change: statin group (n 
1), 2.4  2.0; diet group (n  21), 1.3  2.1; p 
.001]. Changes of cIBS values were significantly correlated
ith changes of TC (r  0.50; p  0.001; Fig. 6A) and
DL-C (r0.62; p 0.001; Fig. 6B) levels but not with
hose of HDL (r  0.23; p  0.080), TG (r  0.06; p 
.65), and hsCRP (r  0.24; p  0.06) from baseline to
ollow-up. Multiple regression analysis revealed that only
hange of LDL-C levels was significantly and indepen-
ently associated with increased cIBS (r  0.59; p 
t Therapy
Diet
-Up Baseline Follow-Up
18*‡ 193  24 185  22†‡
14*‡ 126  22 122  16‡
16† 50  12 48  10
60) 118 (92–144) 114 (84–129)
–0.11)†§ 0.14 (0.05–0.28) 0.13 (0.05–0.34)§
–2.69) 2.07 (1.68–2.42) 1.91 (1.64–2.31)
3.7*‡ 18.2  4.0 18.9  3.5‡Die
ollow
70 
99 
54 
(69–1
(0.04
(2.00
.9 w-up.
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Ultrasound Evaluation of Plaque Stabilization December 6, 2005:2022–30.002). Logistic regression analysis with variables listed in
able 1 identified only statin therapy as an independent and
ignificant predictive factor for improvement of cIBS values
p  0.001; odds ratio 14.7; 95% CI 3.5 to 61.4). Plaque-
MTmax was not significantly changed in both groups from
aseline to follow-up (Fig. 5). Integrated backscatter values
f the adventitia were not significantly different at baseline
nd follow-up in the two treatment groups and not signif-
cantly different from baseline to follow-up within each
roup (statin group: from 54.7  3.7 dB to 54.6  4.0 dB;
 NS; diet group: from 54.2  4.3 dB to 54.0  4.8 dB;
 NS). Eleven patients in the statin group (37%) and 10
atients in the diet group (33%) had calcification in carotid
laques at baseline (p 0.79). We found no change of these
alcified lesions between baseline and follow-up.
linical outcome during follow-up. No patient withdrew
ecause of drug-related side effects, and no major adverse
igure 2. Reduction values of total cholesterol (T-CHO) and low-density
ollow-up period. The box and whisker plots show that the reduction value
roup than in the diet group (p  0.001).
igure 3. Representative multispectral magnetic resonance images of echo
s shown by gray arrowheads. CCA  common carotid artery; ICA
oppler-ultrasound. (C) Short-axis Doppler-ultrasound image of carotid aroton density-weighted (PDW) image. (G) Time-of-flight (TOF) image. W
ndicates the carotid vein.ardiovascular events (sudden cardiac death and acute cor-
nary syndrome) were observed in either group during the
ollow-up period.
ISCUSSION
he present study demonstrates that intensive lipid-
owering therapy by pravastatin significantly improves echo-
enicity of carotid plaques without significant regression of
laque size during short-term follow-up in nonhypercho-
esterolemic patients with CAD. This result suggests that
ntensive lipid-lowering therapy by pravastatin may contrib-
te to plaque stabilization from an early stage of treatment
ven in nonhypercholesterolemic patients. This study also
evealed that quantitative evaluation of vulnerability of
theroma by carotid ultrasound with IBS is possible. Fur-
hermore, it suggests that this clinical strategy may be useful
rotein cholesterol (LDL-C) in the statin group and diet group during the
tal cholesterol (A) and LDL-C (B) were significantly greater in the statin
carotid plaques. (A) High-resolution B-mode image of carotid atheroma
ternal carotid artery. (B) Presence of echolucent plaque visualized by
ma. (D) T1-weighted (T1W) image. (E) T2-weighted (T2W) image. (F)lipop
s of tolucent
 in
therohite arrowheads indicate adventitia of carotid artery, and the asterisk
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December 6, 2005:2022–30 Ultrasound Evaluation of Plaque Stabilizationor evaluating the effects of treatment against atherosclerosis
imed at achieving plaque stabilization. This novel concept
f quantitative evaluation and monitoring of atheroma
uality by ultrasound follow-up can be introduced into
urrent clinical management of patients with CAD.
onitoring echolucent plaques and plaque stabilization.
revious studies have shown that statin therapy decreases
he frequency of cardiovascular events without causing
ignificant changes of vessel lumen diameter (24), raising
he concept of plaque stabilization rather than regression.
ecently, Takano et al. (7) demonstrated that one-year
tatin therapy improves coronary angioscopic findings in
igure 4. Representative IBS images of carotid atheroma from baselin
laque-IMTmax of this plaque are17.8 dB and 2.05 mm, respectively. (B)
nd plaque-IMTmax of this plaque are 14.2 dB and 2.10 mm, respective
igure 5. Changes of cIBS and plaque-IMTmax values from baseline to foll
ncreased echogenicity from baseline to follow-up, whereas diet therapy did
han in the diet group (p  0.001). (C) Plaque-IMTmax values were not signifi
egression values of plaque-IMTmax were not significantly different between thatients with CAD. However, it is difficult for physicians to
erify plaque stabilization in patients in the clinical setting.
arious promising new methods to assess plaque vulnera-
ility have been reported (6–9), although practical exami-
ations to determine whether current treatments are effec-
ive in plaque stabilization have not been established.
cholucent plaques have been characterized as lipid-rich
25) and macrophage-rich lesions (19), and increases of
laque echogenicity indicate improvement of plaque vulner-
bility (16). In the present study, we noninvasively measured
laque echogenicity by high-resolution carotid ultrasound
ith IBS and investigated the effects of plaque stabilization
ollow-up. (A) Carotid atheroma at pretreatment. Values of cIBS and
ame carotid atheroma post-pravastatin therapy (6 months). Values of cIBS
bbreviations as in Figure 1.
p in the two treatment groups. (A) Statin therapy significantly (p  0.001)
B) The increase in cIBS values was significantly greater in the statin groupe to f
The sow-u
not. (cantly changed from baseline to follow-up in either treatment group. (D)
e statin group and diet group. Abbreviations as in Figure 1.
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Ultrasound Evaluation of Plaque Stabilization December 6, 2005:2022–30herapy by comparing and evaluating time-dependent
hanges of echogenicity in the target plaques. Monitoring
cholucent plaques may provide meaningful information on
hanges of plaque vulnerability. Recently, we demonstrated
hat the presence of echolucent carotid plaques as assessed
y carotid ultrasound with IBS is a useful predictor of
ardiovascular events in patients with CAD (14), and there
re reports that carotid plaques are significantly correlated
ith CAD (12,13). Because atherosclerosis is a systemic
isease (26,27), it is thought that stabilization of carotid
laques may reflect stabilization of plaques elsewhere in the
asculature, including coronary atheroma.
ffects of statins on plaque vulnerability assessed by
chogenicity. In this study, significant decreases of TC and
DL-C levels were observed by statin therapy in nonhy-
ercholesterolemic patients. Furthermore, significant in-
reases of carotid echogenicity assessed by cIBS values were
oted in the statin group but not in the diet group,
ndicating successful improvement of plaque vulnerability by
tatins even in nonhypercholesterolemic patients. Previous
linical trials have demonstrated beneficial effects of statins
ithin six-month treatment periods (1,28), suggesting early
ffects of this therapy on atherosclerotic plaques. The
resent study provides further evidence that intensive lipid-
owering therapy by statins may stabilize vulnerable human
theroma from an early stage of treatment.
“Pleiotropic effects” of statins against vascular diseases
ave been postulated (29). We found significant decrease of
sCRP by pravastatin therapy independent of LDL-C
eduction (r  0.19; p  0.14), suggesting existence of
leiotropic effects of pravastatin on hsCRP levels. Mean-
hile, there was significant correlation between changes of
IBS values (carotid echogenicity) and reduction of lipopro-
ein levels during the follow-up period. The interception
alue of change of cIBS at the point of no change of
DL-cholesterol level is below zero (0.598 dB) in this
igure 6. Relationship between the changes of cIBS values and of lipopro
orrelated with the change of total cholesterol (T-CHO) (A) and low-dens
.001). cIBS  calibrated integrated backscatter.tudy (Fig. 6B), suggesting that there were only slight pleiotropic effects of pravastatin on improvement of plaque
chogenicity. The present results also indicate that intensive
ipid-lowering therapy itself, but not cholesterol-
ndependent effects, gives rise to plaque stabilization even in
onhypercholesterolemic patients with CAD.
laque stabilization in nonhypercholesterolemic patients
y statin. Historic landmark clinical trials have clearly
emonstrated beneficial effects of statin therapy in reducing
ardiovascular events in hypercholesterolemic patients (1),
ut whether similar effects could be achieved in nonhyper-
holesterolemic patients was uncertain (30). The Heart
rotection Study sensationally demonstrated that statins are
ffective in preventing cardiac complications even in non-
ypercholesterolemic patients (31). Very recently, Cannon
t al. (32) have shown that aggressive lipid lowering by
tatins provides good clinical prognosis in CAD patients
fter acute coronary syndrome. However, many physicians
ay still tend to hesitate giving statins to nonhypercholes-
erolemic patients with CAD even after large clinical trials
ave shown benefits of this drug class in similar populations
2,31). The present study monitored the direct effects of
tatins on plaque echogenicity, reflecting plaque vulnerabil-
ty, and clearly showed improvement of atheromatous
laques in nonhypercholesterolemic patients with CAD.
hese results confirm statins’ effectiveness in achieving
laque stabilization. Surprisingly on the other hand, lipid-
owering effects by diet therapy alone were not very good in
he present study even though diet therapy and lifestyle
odification are known to prevent atherosclerosis and are a
ell-established strategy in the management of some CAD
atients who may respond to the nonpharmacologic ap-
roach. We never deny beneficial effects and clinical signif-
cance of the diet therapy for prevention of cardiovascular
omplications.
tudy limitations. The first limitation of this study was the
mall size of the patient groups. The second is that sup-
evels from baseline to follow-up. The change of cIBS values significantly
oprotein cholesterol (LDL-C) (B) levels from baseline to follow-up (p tein lression of cardiovascular events could not be verified
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rospective study of carotid ultrasound evaluation with IBS
n a large number of patients is required. Recently Schmidt
t al. (33) reported that beneficial effects of multiple risk
ntervention during six-year follow up were confined to
hose patients with echolucent plaques in the carotid artery.
ur study strongly supports those results and demonstrated
hat the effects appear early during six months of treatment.
he third limitation is that spreading inflammation has
een shown in atherosclerotic adventitia (34), and echo
ntensity in adventitia could be affected by acoustic attenu-
tion due to the presence of thick plaques. Because we
dopted the adventitia as a reference object when calculating
BS values, there is some possibility that adventitial inflam-
ation and acoustic attenuation by plaque itself may have
nfluenced adventitial echogenicity. On the other hand, we
id not observe any change of IBS values in adventitia
etween baseline and follow-up; therefore we assume that
he adventitia is a sufficiently reliable reference object to
valuate plaque echogenicity, as described previously
16,20,21,35). The fourth caveat is that not only lipid-rich
ore but also mural thrombus on carotid plaques and
ntraplaque hemorrhage might be recognized as echolucent
laques. We are unable to confirm whether mural thrombus
nd intraplaque hemorrhage were mistaken as echolucent
laques in the present study. However, mural thrombus on
arotid plaques and intraplaque hemorrhage are usually
bserved in symptomatic patients, e.g., with acute phase of
troke. It is less likely that the echolucent plaques targeted in
he present study were such entities, because our cohort of
atients all had stable CAD without acute symptom of brain
schemia. In future studies, MRI examination of carotid
laques may be helpful in clinical identification of lesions at
aseline (23). Finally, although short-term statin therapy
id not reduce carotid plaque-IMTmax in the present study,
kazaki et al. (36) recently demonstrated that statins reduce
oronary plaque volume as examined by intravascular ultra-
ound at 6 months’ treatment in patients with acute coro-
ary syndrome. Better technical development of carotid
laque volume measurement by ultrasound may provide
ore detailed information about regression of plaque vol-
me by pharmacologic interventions, including statins.
ONCLUSIONS
uantitative noninvasive short-term follow-up of echolu-
ent plaques by carotid ultrasound with IBS to investigate
uality changes of atheroma may be clinically useful for
valuating effects of lipid-lowering treatments aimed at
laque stabilization, even in nonhypercholesterolemic pa-
ients with CAD. Clinical strategies whereby quantitative
nalysis of plaque vulnerability by carotid ultrasound with
BS is employed may be valuable and important for the
reatment of patients with established atherosclerosis.eprint requests and correspondence: Dr. Seigo Sugiyama,
-1-1 Honjo, Kumamoto City, Kumamoto, Japan 860-8556.
-mail: ssugiyam@kumamoto-u.ac.jp.
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